Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer

OBJECTIVE: The objective of this open-label, randomized study was to compare dose-dense paclitaxel plus carboplatin (PCdd) with dose-dense epirubicin and cyclophosphamide followed by paclitaxel (ECdd-P) as an adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: We included...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Chin J Cancer Res
Главные авторы: Li, Qing, Wang, Jiani, Mu, Yuxin, Zhang, Tongtong, Han, Ying, Wang, Jiayu, Li, Qiao, Luo, Yang, Ma, Fei, Fan, Ying, Zhang, Pin, Xu, Binghe
Формат: Artigo
Язык:Inglês
Опубликовано: AME Publishing Company 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7491545/
https://ncbi.nlm.nih.gov/pubmed/32963461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2020.04.06
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы